ANPCF - Angle Parsortix system gets FDA nod for harvesting cancer cells for analysis

Angle (OTC:ANPCF) (OTCQX:ANPCY) said that the U.S. Food and Drug Administration (FDA) cleared Parsortix system for use in harvesting cancer cells from blood of patients with metastatic breast cancer (MBC) for subsequent analysis. The company said it is first ever FDA product clearance to harvest cancer cells from a patient blood sample for subsequent analysis. Angle noted that the FDA granted a De Novo Class 2 classification to Parsortix. Angle said that the test has the potential to transform treatment decisions for cancer patients as it provides an opportunity for repeat non-invasive biopsies to assess cancer status.

For further details see:

Angle Parsortix system gets FDA nod for harvesting cancer cells for analysis